001     9643
005     20180208195229.0
024 7 _ |2 DOI
|a 10.1149/1.3382944
024 7 _ |2 WOS
|a WOS:000277260200080
024 7 _ |2 ISSN
|a 0013-4651
024 7 _ |2 ISSN
|a 0096-4743
024 7 _ |2 ISSN
|a 0096-4786
024 7 _ |2 ISSN
|a 1945-7111
037 _ _ |a PreJuSER-9643
041 _ _ |a eng
082 _ _ |a 540
084 _ _ |2 WoS
|a Electrochemistry
084 _ _ |2 WoS
|a Materials Science, Coatings & Films
100 1 _ |0 P:(DE-Juel1)125595
|a Holländer, B.
|b 0
|u FZJ
245 _ _ |a Wet Chemical Etching of Si, Si1-xGex, and Ge in HF:H2O2:CH3COOH
260 _ _ |a Pennington, NJ
|b Electrochemical Society
|c 2010
300 _ _ |a H643 - H646
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
440 _ 0 |0 3889
|a Journal of the Electrochemical Society
|v 157
|x 0013-4651
|y 6
500 _ _ |a This work was supported by the European Commission, Information Society Technology (IST), within the framework of PULLNANO, contract no. IST-026828.
520 _ _ |a This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
536 _ _ |0 G:(DE-Juel1)FUEK412
|2 G:(DE-HGF)
|a Grundlagen für zukünftige Informationstechnologien
|c P42
|x 0
588 _ _ |a Dataset connected to Web of Science, Pubmed
650 _ 7 |2 WoSType
|a J
700 1 _ |0 P:(DE-Juel1)125569
|a Buca, D.
|b 1
|u FZJ
700 1 _ |0 P:(DE-Juel1)VDB4959
|a Mantl, S.
|b 2
|u FZJ
700 1 _ |0 P:(DE-HGF)0
|a Hartmann, J.M.
|b 3
773 _ _ |0 PERI:(DE-600)2002179-3
|a 10.1149/1.3382944
|g Vol. 157, p. H643 - H646
|p H643 - H646
|q 157|t Journal of the Electrochemical Society
|v 157
|x 0013-4651
|y 2010
856 7 _ |u http://dx.doi.org/10.1149/1.3382944
909 C O |o oai:juser.fz-juelich.de:9643
|p VDB
913 1 _ |0 G:(DE-Juel1)FUEK412
|a DE-HGF
|b Schlüsseltechnologien
|k P42
|l Grundlagen für zukünftige Informationstechnologien (FIT)
|v Grundlagen für zukünftige Informationstechnologien
|x 0
914 1 _ |y 2010
915 _ _ |0 StatID:(DE-HGF)0010
|a JCR/ISI refereed
920 1 _ |d 31.12.2010
|g IBN
|k IBN-1
|l Halbleiter-Nanoelektronik
|0 I:(DE-Juel1)VDB799
|x 0
920 1 _ |0 I:(DE-82)080009_20140620
|k JARA-FIT
|l Jülich-Aachen Research Alliance - Fundamentals of Future Information Technology
|g JARA
|x 1
970 _ _ |a VDB:(DE-Juel1)119578
980 _ _ |a VDB
980 _ _ |a ConvertedRecord
980 _ _ |a journal
980 _ _ |a I:(DE-Juel1)PGI-9-20110106
980 _ _ |a I:(DE-82)080009_20140620
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)PGI-9-20110106
981 _ _ |a I:(DE-Juel1)VDB881


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21